Quest Diagnostics
DGX | NYSE
$234.02
-$10.86 (-4.43%)
Sep 22, 2026, 12:26 PM ET · Market open
Company Profile
Quest Diagnostics Incorporated, founded in 1967 and headquartered in Secaucus, New Jersey, is a premier provider of diagnostic testing, information, and related services, serving clients both domestically and internationally. Its core business involves the development and provision of diverse diagnostic information services, such as routine, advanced clinical, and anatomic pathology testing. While primarily operating under the Quest Diagnostics brand, it also leverages specialized identities like AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum to reach a broad spectrum of clients. Its extensive client base includes patients, clinicians, hospitals, integrated delivery networks, health plans, employers, and other direct healthcare entities. Delivery of these services is facilitated through a robust network comprising laboratories, patient service centers, in-office phlebotomists, call centers, and mobile health professionals including paramedics and nurses. Additionally, the company provides risk assessment services for the life insurance industry and offers comprehensive information technology solutions to healthcare organizations and clinicians.
Key Executives
| Name | Position |
|---|---|
| James E. Davis | Chairman, Chief Executive Officer & President |
| Sam A. Samad | Executive Vice President & Chief Financial Officer |
| Catherine T. Doherty | Executive Vice President of Regional Businesses |
| Damini Chokshi | Vice President of Investor Relations |
| Dan Haemmerle | Interim VP of Investor Relations & VP Finance |
| Garry Clark | Senior Vice President and Chief Marketing & Communications Officer |
| Karthik Kuppusamy | Senior Vice President of Clinical Solutions |
| Kristin Lee Wallace | Senior Vice President & Chief Compliance Officer |
| Michael E. Prevoznik | Senior Vice President & General Counsel |
| Michael J. Deppe | Senior Vice President, Corporate Controller & Chief Accounting Officer |
| Murali Balakumar | Senior Vice President and Chief Information & Digital Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Sep 03, 2026 | 4 | Filing |
| Aug 31, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Jul 29, 2026 | 4 | Filing |
| Jul 27, 2026 | 4 | Filing |
| Jul 27, 2026 | 4 | Filing |
| Jul 27, 2026 | 4 | Filing |
| Jul 27, 2026 | 4 | Filing |
| Jul 27, 2026 | 4 | Filing |
| Jul 27, 2026 | 4 | Filing |
Quest Diagnostics
| Country | United States |
| IPO Date | Dec 16, 1996 |
| Industry | Medical - Diagnostics & Research |
| Sector | Healthcare |
| Employees | 51,500 |
| CEO | James E. Davis |
Contact Details
500 Plaza Drive Secaucus,
New Jersey 07094 United States
Stock Details
| Ticker Symbol | DGX |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001022079 |
| CUSIP Number | 74834L100 |
| ISIN Number | US74834L1008 |
| SIC Code | 8071 |
Recent News
- 4 hours ago / fool.comWhy Quest Diagnostics Holdings Stock Dropped Today
- 5 hours ago / zacks.comQuest Diagnostics Study Finds High Tick-Borne Disease Co-Exposure
- 6 hours ago / zacks.comIs This the Right Time to Add DGX Stock to Your Portfolio?
- 1 day ago / marketbeat.comQuest Diagnostics Sees Growth Outpace Targets as Consumer Testing Surges
- 1 day ago / prnewswire.comNearly 1 in 3 Patients with Suspected Lyme Disease are Co-Positive for Other Tick-Borne Pathogens, Finds Study by Quest Diagnostics
- 6 days ago / zacks.comQuest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
- 6 days ago / prnewswire.comNine in 10 Voters Express Concern That Medicare Lab Payment Cuts Will Harm Patient Access to Diagnostic Lab Testing, Finds National Survey from Quest Diagnostics
- 7 days ago / seekingalpha.comQuest Diagnostics Incorporated (DGX) Presents at 2026 Global Healthcare Conference Transcript
- 8 days ago / zacks.comQuest Diagnostics (DGX) is a Top-Ranked Momentum Stock: Should You Buy?
- 22 days ago / zacks.comQuest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
Add to Watchlist
Select watchlists to add or remove DGX